Allegheny-Singer Research Inst — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2022	Research	$47,550	3
2021	Research	$11,082	9
2020	Research	$217,429	30
2019	Research	$400,772	35

Breakdown

Who paid Research payments · program years 2019–2022

United Therapeutics Corporation $443,134 44 payments
Hoffmann-La Roche Limited $120,652 8 payments
F. Hoffmann-La Roche AG $75,409 12 payments
Eisai Inc. $19,183 3 payments
Genentech, Inc. $16,955 9 payments
Celgene Corporation $1,500 1 payment

Studies the money was for Research payments · program years 2019–2022

Whole Genome Sequencing in PAH $348,094 3 payments
An Open Label Randomized Multicenter Study to Investigate Pharmacokinetics Pharmacodynamics Safe $120,652 8 payments
An Open-Label Extension Study of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease $47,877 20 payments
Histology and Long Term Outcomes in Ulcerative Colitis $45,600 2 payments
A Multicenter Randomized Double-Blinded Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease $29,009 10 payments
1L Nsclc DX All Comer Non Squamous $25,750 7 payments
A Retrospective Multicenter Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy $19,183 3 payments
PH III Open Label Study Atezo VS BSC Following Adjuvant Chemo in Stage Ib Iiia Nsclc $16,955 9 payments
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension PH in Heart Failure With Preserved Ejection Fraction Hfpef $11,384 6 payments
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (Hfpef) $4,267 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.